



The characteristics of human embryonic stem cells (hESCs) that make them attractive candidates for cell-based therapies also make
themwell suited for large-scale screening applications. In this issue, Studer and colleagues describe an hESC screening platform and
use it to identify small molecules that can promote either the maintenance or the differentiation of pluripotent cells. Their Resource
article highlights the power of this system for drug development and characterization. A small molecule screening approach was also
used by the Ding laboratory in a Correspondence article in this issue. In this case, the authors identify soluble factors that limit the
requirement for viral transduction to generate induced pluripotent stem cells (iPSCs) or improve the efficiency of the reprogramming
process. The continuing rapid pace of the pluripotent reprogramming field is certainly remarkable, and it is underscored by the list of
high-caliber primary and review articles thatCell Stem Cell has published on the topic. To celebrate our first anniversary, readers can
enjoy free online access to our iPSC collection, as well as a selection of other popular research and review format articles.
Balancing Life and Death
Cancer patients who receive radiotherapy are at risk of GI syndrome, due to intestinal stem cell damage. In an article from Qiu and
colleagues, the p53-regulated protein PUMA is revealed as a potential therapeutic target to prevent this adverse event. The
authors show that Puma-deficient mice exhibit reduced irradiation-induced apoptosis in the intestine,
and subsequently improved crypt survival. In addition, experimental knockdown of Puma minimized intes-
tinal damage in response to ionizing radiation. Meanwhile, two other studies in this issue demonstrate that
classic apoptotic proteins can participate in stem cell regulation via novel pathways. In one, Zwaka and
colleagues demonstrate that Caspase-3-deficient ESCs are unable to differentiate effectively and suggest
that normal progression requires caspase cleavage of Nanog. In the other article, Janzen et al. observe
that hematopoietic stem cells accumulate in Caspase-3 knockout mice and display altered differentiation
potential. Notably, the phenotypes in both cases could not be attributed to deficiencies in the apoptotic
pathway. Collectively, these three studies highlight the challenge inherent in dissecting the specific signals
that interact to balance stem cell fate.
Policy versus Publication, and Beyond
Many articles in both the scientific and popular press propose that restrictive legislation and limited funding for hESC studies have
a negative impact on research advances. While a direct effect of regional policy on scientific productivity is essentially impossible to
prove, a Correspondence article in this issue fromAaron Levine reveals an interesting correlation. By comparing three data sets com-
posed of journal articles that cite either the original hESC report from Thomson, the original RNAi report fromMello, or a collection of
high-impact biomedical papers published in the same time frame, Levine identified six countries that either ‘‘over-’’ or ‘‘underper-
form’’ in producing hESC-related research. The analysis offers a quantitative assessment of national publication records and should
serve to inform policy discussions internationally. Clearly, considerable attention has been paid to the ethical concerns surrounding
hESC research, many of which are hailed by some as ‘‘solved’’ by the isolation of iPSCs. However, it is important not to lose sight of
other existing ethical concerns that apply to all stem cell research, as well as some new issues that have been raised now that iPSCs
are on the scene. To outline some of these important points, and draw attention to some ‘‘older’’ concerns that continue to face the
stem cell field, Jeremy Sugarman offers the first article in our new ‘‘Forum’’ format.
Taking It to the Clinic
In addition to concerns regarding the procurement and handling of stem cells to be used in eventual clinical
applications, proper design of potential cell-based interventions relies heavily on the selection of appropriate
target medical conditions. A proof-of-principle study using an animal model of congenital myelin deficiencies
presented in this issue offers important insight into human candidate selection. Goldman and colleagues used
a multiple injection protocol to transfer high numbers of human fetal oligodendrocyte progenitors into the
brains of fatally myelin-deficient, immune-compromised mice. Remarkably, a significant portion of the treated
cohort not only survived, but also experienced complete symptom reversal correlating with extensive, diverse
engraftment of functional human cells. The authors propose that the cell source, mode of injection, and age of
recipient contributed to the success of the protocol. These findings underscore the importance of targeting the
right cells to the right place(s) at the right time and should help to inform those designing translational trials with
human subjects. The application of regenerative medicine advances to other cell, tissue, and organ types is
obviously of tremendous interest. In this issue’s Review article, Reh and colleagues describe the regenerative processes at work
in the retina ofmany species and discuss how lessons learned from the developmental biology of the eyemight one day be harnessed
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